Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder
Carregando...
Citações na Scopus
26
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.67, n.4, p.335-340, 2012
Resumo
OBJECTIVES: Approximately 40-60% of obsessive-compulsive disorder patients are nonresponsive to serotonin reuptake inhibitors. Genetic markers associated with treatment response remain largely unknown. We aimed (1) to investigate a possible association of serotonergic polymorphisms in obsessive-compulsive disorder patients and therapeutic response to selective serotonin reuptake inhibitors and (2) to examine the relationship between these polymorphisms and endocrine response to intravenous citalopram challenge in responders and non-responders to serotonin reuptake inhibitors and in healthy volunteers. METHODS: Patients with obsessive-compulsive disorder were classified as either responders or non-responders after long-term treatment with serotonin reuptake inhibitors, and both groups were compared with a control group of healthy volunteers. The investigated genetic markers were the G861C polymorphism of the serotonin receptor 1D beta gene and the T102C and C516T polymorphisms of the serotonin receptor subtype 2A gene. RESULTS: The T allele of the serotonin receptor subtype 2A T102C polymorphism was more frequent among obsessive-compulsive disorder patients (responders and non-responders) than in the controls (p<0.01). The CC genotype of the serotonin receptor subtype 2A C516T polymorphism was more frequent among the non-responders than in the responders (p<0.01). The CC genotype of the serotonin receptor subtype 1D beta G681C polymorphism was associated with higher cortisol and prolactin responses to citalopram (p<0.01 and p<0.001, respectively) and with a higher platelet-rich plasma serotonin concentration among the controls (p<0.05). However, this pattern was not observed in the non-responders with the same CC genotype after chronic treatment with serotonin reuptake inhibitors. This CC homozygosity was not observed in the responders.
Palavras-chave
Pharmacogenetics, Serotonin Receptor Subtype 1D beta, Serotonin Receptor Subtype 2A, Citalopram, Challenge Test
Referências
- American Psychiatric Association, 1994, DIAGN STAT MAN MENT
- BLIER P, 1987, J CLIN PSYCHOPHARM, V7, pS24
- Cavallini MC, 1998, PSYCHIAT RES, V77, P97
- CHOPIN P, 1994, PHARMACOL THERAPEUT, V62, P385, DOI 10.1016/0163-7258(94)90051-5
- Collier DA, 2003, DRUG NEWS PERSPECT, V16, P159, DOI 10.1358/dnp.2003.16.3.737958
- Corregiari FM, 2007, PSYCHOPHARMACOLOGY, V193, P487, DOI 10.1007/s00213-007-0793-0
- Denys D, 2007, J CLIN PSYCHIAT, V68, P747
- Hounie AG, 2008, NEUROSCI LETT, V442, P86, DOI 10.1016/j.neulet.2008.07.022
- KIM SW, 1990, PSYCHIAT RES, V34, P99, DOI 10.1016/0165-1781(90)90061-9
- LEON AC, 1992, SOC PSYCH PSYCH EPID, V27, P78, DOI 10.1007/BF00788510
- Meira-Lima I, 2004, GENES BRAIN BEHAV, V3, P75, DOI 10.1046/j.1601-183x.2003.00042.x
- Miguita K, 2011, ARQ NEURO-PSIQUIAT, V69, P283
- MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
- Mongeau R, 1997, PSYCHOPHARMACOLOGY, V131, P321, DOI 10.1007/s002130050299
- Mundo E, 2002, MOL PSYCHIATR, V7, P805, DOI 10.1038/sj.mp.4001059
- Ott J., 1988, UTILITY PROGRAMS ANA
- Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
- Pigott TA, 1999, J CLIN PSYCHIAT, V60, P101
- Silva MA, 2005, REV MED CHILE, V133, P1392
- Stein DJ, 2002, LANCET, V360, P397, DOI 10.1016/S0140-6736(02)09620-4
- Szeszko JS, 2006, DIABETES, V55, P559, DOI 10.2337/diabetes.55.02.06.db05-0826
- WARREN JT, 1993, HUM MOL GENET, V2, P338, DOI 10.1093/hmg/2.3.338
- Ziegler A, 2011, BREAST CANCER RES TR, V128, P197, DOI 10.1007/s10549-010-1295-z
- [Anonymous], 1995, LANCET, V346, P281